( NASDAQ-NMS:ARNA )

News from Arena Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 10, 2017, 11:31 ET Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative...


Nov 07, 2017, 16:01 ET Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today provided a corporate update and reported financial results for the third quarter ended September...


Oct 31, 2017, 08:30 ET Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Kevin R. Lind, the Company's Executive Vice President and Chief Financial Officer,...


Oct 30, 2017, 08:30 ET Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2017 financial results and provide a...


Oct 19, 2017, 08:30 ET Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that results of the Phase 2 clinical study of ralinepag (APD811), the Company's...


Sep 06, 2017, 08:30 ET Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag...


Aug 29, 2017, 08:30 ET Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will participate in the following investor...


Aug 22, 2017, 08:30 ET Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag...


Aug 07, 2017, 16:01 ET Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple...


Jul 31, 2017, 16:32 ET Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2017 financial results and provide a...


Jul 31, 2017, 08:30 ET Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the underwriters of its previously announced underwritten public offering of...


Jul 12, 2017, 20:11 ET Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock...


Jul 11, 2017, 16:05 ET Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, $150.0...


Jul 10, 2017, 16:01 ET Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally...


Jun 29, 2017, 08:30 ET Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the completion of a Phase 1 comparative bioavailability study evaluating the...


Jun 15, 2017, 08:30 ET Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit Munshi, the Company's President and Chief Executive Officer, will present a...


Jun 14, 2017, 16:01 ET Arena Pharmaceuticals Announces Shareholders and Board of Directors Approve Reverse Stock Split

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that at the annual meeting of stockholders, held June 13, 2017, stockholders voted to...


Jun 14, 2017, 08:30 ET Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the appointment of Jennifer Jarrett to the Company's Board of Directors. Ms. Jarrett...


Jun 01, 2017, 08:30 ET Arena Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference June 9th

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will present a corporate update at the...


May 18, 2017, 08:30 ET Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on the...


May 16, 2017, 16:30 ET Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective...


May 09, 2017, 16:01 ET Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple...


May 02, 2017, 08:30 ET Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple...


Apr 21, 2017, 16:01 ET Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of its previously announced underwritten public offering of 69,000,000...


Apr 17, 2017, 22:15 ET Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 60,000,000 shares of its common stock,...